Traws Pharma ( (TRAW) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Traws Pharma, Inc. has filed a Form 12b-25 to notify investors of a delayed Annual Report on Form 10-K (Yearly Report) for the year ended December 31, 2025. The company’s filing covers its full-year 2025 results and indicates a short-term delay in submitting the audited financial statements to the SEC.
Management explains that the delay stems from ongoing financing efforts needed to support operations and maintain compliance with Nasdaq’s minimum stockholders’ equity rule. Because no financing agreement has yet been finalized, the company needs additional time to evaluate how any potential deals may affect its financial statements and going-concern disclosures.
The company also notes that its auditor, KPMG LLP, must complete additional audit procedures once management finalizes its assessment of financing transactions and going-concern considerations. This sequencing of internal review and external audit work has contributed to the timing issues around the Form 10-K (Yearly Report) completion.
Traws Pharma states that it expects to file the Form 10-K (Yearly Report) within the standard 15-day extension window allowed under SEC Rule 12b-25. Investors should therefore anticipate the annual filing to be made shortly after the original due date, assuming no unexpected complications arise.
Despite the delay, the company offers preliminary 2025 numbers that point to a dramatic improvement in headline results. Traws Pharma expects to report approximately $2.8 million in revenue for 2025, up from $0.2 million in 2024, driven by increased business activity compared with the prior year.
The company also anticipates recording about $26.7 million of income related to a change in the fair value of a warrant liability during 2025, versus none in 2024. Combined with the nonrecurrence of a $117.5 million acquired in-process R&D write-off booked in 2024, these items are expected to transform the bottom line from a deep loss to a profit.
As a result of these factors, Traws Pharma projects net income of roughly $9.2 million for 2025, compared with a net loss of about $166.5 million in 2024. Management stresses that these figures are preliminary, unaudited and subject to change as the year-end close and audit processes are finalized.
The company cautions that the final results included in the Form 10-K (Yearly Report) may differ materially from the preliminary estimates and urges investors not to place undue reliance on the early data. These statements are effectively forward-looking and depend on completing the financial close, audit work and any financing decisions.
Traws Pharma emphasizes that it is working diligently to complete the filing and to address its capital needs while staying in line with Nasdaq listing standards. The notification is signed by Chief Financial Officer Charles Parker and audit committee directors Jack Stover, John Leaman and Trafford Clarke, underscoring board-level oversight of the delayed filing and compliance process.
The most recent analyst rating on (TRAW) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.
The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. is a U.S.-based biopharmaceutical company headquartered in Newtown, Pennsylvania. The company develops pharmaceutical products and, like many early-stage biotech firms, has historically incurred recurring operating losses while relying on external financing to fund its operations and research pipeline.
Average Trading Volume: 195,710
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.98M
For a thorough assessment of TRAW stock, go to TipRanks’ Stock Analysis page.